Year: 2021
Type: review
Abstract: Drugs whose targets have genetic evidence to support efficacy and safety are more likely to be approved after clinical development. In this paper, we provide an overview of how natural sequence variation in the genes that encode drug targets can be used in Mendelian randomization analyses to offer insight into mechanism-based efficacy and adverse effects. Large databases of summary level genetic association data are increasingly available and can be leveraged to identify and validate variants that serve as proxies for drug target perturbation. As with all empirical research, Mendelian randomization has limitations including genetic confounding, its consideration of lifelong effects, and issues related to heterogeneity across different tissues and populations. When appropriately applied, Mendelian randomization provides a useful empirical framework for using population level data to improve the success rates of the drug development pipeline.
Source: Wellcome Open Research
Authors: Dipender Gill, Marios K. Georgakis, Venexia M. Walker, A. Floriaan Schmidt, Apostolos Gkatzionis, Daniel F. Freitag, Chris Finan, Aroon D. Hingorani, Joanna M.M. Howson, Stephen Burgess, Daniel I. Swerdlow, George Davey Smith, Michael V. Holmes, Martin Dichgans, Robert A Scott, Jie Zheng, Bruce M. Psaty, Neil M. Davies
Institutions: National Health Service, St George's Hospital, St George's, University of London, St George’s University Hospitals NHS Foundation Trust, Novo Nordisk (United Kingdom), Imperial College London, Institut für Schlaganfall- und Demenzforschung, Ludwig-Maximilians-Universität München, University of Bristol, MRC Integrative Epidemiology Unit, University of Pennsylvania, University Medical Center Utrecht, University College London, University of Cambridge, MRC Biostatistics Unit, Bayer (Germany), British Heart Foundation, UCL Biomedical Research Centre, NIHR Bristol Biomedical Research Centre, University of Oxford, MRC Population Health Research Unit, German Center for Neurodegenerative Diseases, Munich Cluster for Systems Neurology, GlaxoSmithKline (United Kingdom), Kaiser Permanente Washington Health Research Institute, University of Washington, Norwegian University of Science and Technology
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,128
Funders: Pfizer, Bayer, GlaxoSmithKline, Yale University, Wellcome Trust, Corona-Stiftung, National Institute for Health and Care Research, British Heart Foundation, Royal Society, Imperial College London, University of Oxford, European Commission, Rosetrees Trust, University of Bristol, Deutscher Akademischer Austauschdienst, Deutsche Forschungsgemeinschaft, Fondation Leducq, Seoul National University, Novo Nordisk, Alexander S. Onassis Public Benefit Foundation, Norges Forskningsråd, Silence Therapeutics, Medical Research Council, St. George's, University of London, UCLH Biomedical Research Centre, National Heart, Lung, and Blood Institute
Awards: G1474772629, NIHR Senior Investigator Award, Research Excellence (round 3), G149876332, G161284949, G1643655829, NIHR Senior Investigator Award, G1801186217, Small vessel diseases in a mechanistic perspective: Targets for Intervention Affected pathways and mechanistic exploitation for prevention of stroke and dementia, Large-scale integrative genomic studies of high-dimensional traits in cardiovascular diseases (renewal), G2538597952, G2673957436, G3259981160, G3319528975, The Imperial Immunity, Inflammation, Infection and Informatics (4i) Clinician Scientist Programme, G434337789, G5001017760, Evaluating combination therapeutics for CVD prevention using Mendelian randomization and phenome-wide scans, G571894948, CHARGE consortium: omics discovery for CVD and aging phenotypes, G6228397153, G6476231992, Mendelian randomization to hypothesis-free causal inference, The BHF Chair of Epidemiology and Medicine, Genetics and causality: towards more accessible and more reliable Mendelian randomization investigations, Large-scale integrative studies of risk factors in coronary heart disease: from discovery to application. (renewal) (Joint funding with MRC), G784065502, G7964453685, G8093563686, Common mechanisms and pathways in Stroke and Alzheimer's disease., G8518790725, G8592617908, Drug target validation and risk prediction for coronary heart disease using targeted blood-based metabolomics and proteomics
OpenAlex ID: W3121173001
